Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.

about

Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Methyl jasmonate enhances the radiation sensitivity of esophageal carcinoma cells by inhibiting the 11-ketoprostaglandin reductase activity of

P2860

Q37629548-496E1A20-7C17-49BB-B122-9445C1A20FC5 Q47818730-1325FDF6-C205-42C9-85E4-4AFDC72BA7CA Q58781589-114501AD-C1D2-47E1-86E1-581C76BD7E93

P2860

Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.

Item

http://www.wikidata.org/entity/Q38735379

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Inhibition of AKR1C3 Activatio ...... e in Advanced Prostate Cancer.

@en

type

Item

label

Inhibition of AKR1C3 Activatio ...... e in Advanced Prostate Cancer.

@en

prefLabel

Inhibition of AKR1C3 Activatio ...... e in Advanced Prostate Cancer.

@en

P1476

Inhibition of AKR1C3 Activatio ...... e in Advanced Prostate Cancer.

@en

P2093

Alan Lombard

http://www.w3.org/2001/XMLSchema#string

Allen C Gao

http://www.w3.org/2001/XMLSchema#string

Cameron M Armstrong

http://www.w3.org/2001/XMLSchema#string

Christopher P Evans

http://www.w3.org/2001/XMLSchema#string

Wei Lou

http://www.w3.org/2001/XMLSchema#string

P2860

AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression

Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones

Abiraterone in metastatic prostate cancer without previous chemotherapy

Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

P304

35-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-16-0186

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chengfei Liu

P577

2016-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27794047

http://www.w3.org/2001/XMLSchema#string

P932

5222693

http://www.w3.org/2001/XMLSchema#string

Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.

about

P2860

P2860

Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932